Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis
Hyperhomocysteinemia is common in patients with end-stage renal disease. It is one of the risk factors for cardiovascular disease. We evaluated the effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis. Patients on maintenance hemodialysis were randomized in...
Gespeichert in:
| Veröffentlicht in: | Iranian journal of kidney diseases 2011-03, Vol.5 (2), p.93-96 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 96 |
|---|---|
| container_issue | 2 |
| container_start_page | 93 |
| container_title | Iranian journal of kidney diseases |
| container_volume | 5 |
| creator | Tamadon, Mohamad Reza Jamshidi, Lotfali Soliemani, Alireza Ghorbani, Raheb Malek, Farhad Malek, Mojtaba |
| description | Hyperhomocysteinemia is common in patients with end-stage renal disease. It is one of the risk factors for cardiovascular disease. We evaluated the effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis.
Patients on maintenance hemodialysis were randomized into 4 groups to receive oral folic acid at doses of 2, 5, 10, and 15 mg/d, each for a period of 4 weeks. Serum homocysteine level was measured in all of the patients before and at the end of each week of therapy. Folic acid supplementation was discontinued during a washout period of 1 week between each of the four phases of the trial.
Thirty-one hemodialysis patients completed the four phases of treatment with each dose of folic acid (17 women and 14 men). The mean age of patients was 57.6 ± 14.6 years. Serum homocysteine level was reduced significantly compared to its basal level after treatment with folic acid at different doses (P < .001). Different doses of folic acid were not significantly different in lowering serum homocysteine levels.
Our study failed to show any difference between high-dose and low-dose folic acid therapy regarding their effect on serum homocysteine level. It seems folic acid, 2 mg/d, is an adequate dose, and there is no need to administer a higher dose of it. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_855199334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2324252781</sourcerecordid><originalsourceid>FETCH-LOGICAL-p237t-abffc223e5b571a26ff4422c795b23ee77aeb3fc193a8e82f59dc5fe942ee74c3</originalsourceid><addsrcrecordid>eNpdkE9LAzEQxYMotla_ggQvnhZ28z9HKdUKBS96XrLZCU3JbtbNrtBvb4rtxdM83vze8JgrtKwk5YUSJbu-aK7IAt2ldChLQTUrb9GCVFQoqsQS1RvnwE44Otz6LEfoJ9zGBOlkuRi8xcb6FsceJxjnDu9jF-0xTeB7wAF-IGDf48FMPkfTidtDF1tvwjH5dI9unAkJHs5zhb5eN5_rbbH7eHtfv-yKgVA5FaZxzhJCgTdcVoYI5xgjxErNm-yClAYa6mylqVGgiOO6tdyBZiQvmaUr9Px3dxjj9wxpqjufLIRgeohzqhXnldaUskw-_SMPcR77XK5WgnCpBC8z9HiG5qaDth5G35nxWF8eR38B-Rlr0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>862578650</pqid></control><display><type>article</type><title>Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Tamadon, Mohamad Reza ; Jamshidi, Lotfali ; Soliemani, Alireza ; Ghorbani, Raheb ; Malek, Farhad ; Malek, Mojtaba</creator><creatorcontrib>Tamadon, Mohamad Reza ; Jamshidi, Lotfali ; Soliemani, Alireza ; Ghorbani, Raheb ; Malek, Farhad ; Malek, Mojtaba</creatorcontrib><description>Hyperhomocysteinemia is common in patients with end-stage renal disease. It is one of the risk factors for cardiovascular disease. We evaluated the effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis.
Patients on maintenance hemodialysis were randomized into 4 groups to receive oral folic acid at doses of 2, 5, 10, and 15 mg/d, each for a period of 4 weeks. Serum homocysteine level was measured in all of the patients before and at the end of each week of therapy. Folic acid supplementation was discontinued during a washout period of 1 week between each of the four phases of the trial.
Thirty-one hemodialysis patients completed the four phases of treatment with each dose of folic acid (17 women and 14 men). The mean age of patients was 57.6 ± 14.6 years. Serum homocysteine level was reduced significantly compared to its basal level after treatment with folic acid at different doses (P < .001). Different doses of folic acid were not significantly different in lowering serum homocysteine levels.
Our study failed to show any difference between high-dose and low-dose folic acid therapy regarding their effect on serum homocysteine level. It seems folic acid, 2 mg/d, is an adequate dose, and there is no need to administer a higher dose of it.</description><identifier>ISSN: 1735-8582</identifier><identifier>EISSN: 1735-8604</identifier><identifier>PMID: 21368386</identifier><language>eng</language><publisher>Iran: Iranian Society of Nephrology</publisher><subject>Aged ; Aged, 80 and over ; Cross-Over Studies ; Female ; Folic Acid - administration & dosage ; Folic Acid - therapeutic use ; Homocysteine - blood ; Humans ; Hyperhomocysteinemia - prevention & control ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - therapy ; Male ; Middle Aged ; Renal Dialysis</subject><ispartof>Iranian journal of kidney diseases, 2011-03, Vol.5 (2), p.93-96</ispartof><rights>Copyright Dr Ali Akbari Sari, Director of The Commission for Accreditation & Improvement of Iranian Medical Journals Mar 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21368386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamadon, Mohamad Reza</creatorcontrib><creatorcontrib>Jamshidi, Lotfali</creatorcontrib><creatorcontrib>Soliemani, Alireza</creatorcontrib><creatorcontrib>Ghorbani, Raheb</creatorcontrib><creatorcontrib>Malek, Farhad</creatorcontrib><creatorcontrib>Malek, Mojtaba</creatorcontrib><title>Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis</title><title>Iranian journal of kidney diseases</title><addtitle>Iran J Kidney Dis</addtitle><description>Hyperhomocysteinemia is common in patients with end-stage renal disease. It is one of the risk factors for cardiovascular disease. We evaluated the effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis.
Patients on maintenance hemodialysis were randomized into 4 groups to receive oral folic acid at doses of 2, 5, 10, and 15 mg/d, each for a period of 4 weeks. Serum homocysteine level was measured in all of the patients before and at the end of each week of therapy. Folic acid supplementation was discontinued during a washout period of 1 week between each of the four phases of the trial.
Thirty-one hemodialysis patients completed the four phases of treatment with each dose of folic acid (17 women and 14 men). The mean age of patients was 57.6 ± 14.6 years. Serum homocysteine level was reduced significantly compared to its basal level after treatment with folic acid at different doses (P < .001). Different doses of folic acid were not significantly different in lowering serum homocysteine levels.
Our study failed to show any difference between high-dose and low-dose folic acid therapy regarding their effect on serum homocysteine level. It seems folic acid, 2 mg/d, is an adequate dose, and there is no need to administer a higher dose of it.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cross-Over Studies</subject><subject>Female</subject><subject>Folic Acid - administration & dosage</subject><subject>Folic Acid - therapeutic use</subject><subject>Homocysteine - blood</subject><subject>Humans</subject><subject>Hyperhomocysteinemia - prevention & control</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Renal Dialysis</subject><issn>1735-8582</issn><issn>1735-8604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkE9LAzEQxYMotla_ggQvnhZ28z9HKdUKBS96XrLZCU3JbtbNrtBvb4rtxdM83vze8JgrtKwk5YUSJbu-aK7IAt2ldChLQTUrb9GCVFQoqsQS1RvnwE44Otz6LEfoJ9zGBOlkuRi8xcb6FsceJxjnDu9jF-0xTeB7wAF-IGDf48FMPkfTidtDF1tvwjH5dI9unAkJHs5zhb5eN5_rbbH7eHtfv-yKgVA5FaZxzhJCgTdcVoYI5xgjxErNm-yClAYa6mylqVGgiOO6tdyBZiQvmaUr9Px3dxjj9wxpqjufLIRgeohzqhXnldaUskw-_SMPcR77XK5WgnCpBC8z9HiG5qaDth5G35nxWF8eR38B-Rlr0g</recordid><startdate>20110301</startdate><enddate>20110301</enddate><creator>Tamadon, Mohamad Reza</creator><creator>Jamshidi, Lotfali</creator><creator>Soliemani, Alireza</creator><creator>Ghorbani, Raheb</creator><creator>Malek, Farhad</creator><creator>Malek, Mojtaba</creator><general>Iranian Society of Nephrology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110301</creationdate><title>Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis</title><author>Tamadon, Mohamad Reza ; Jamshidi, Lotfali ; Soliemani, Alireza ; Ghorbani, Raheb ; Malek, Farhad ; Malek, Mojtaba</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p237t-abffc223e5b571a26ff4422c795b23ee77aeb3fc193a8e82f59dc5fe942ee74c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cross-Over Studies</topic><topic>Female</topic><topic>Folic Acid - administration & dosage</topic><topic>Folic Acid - therapeutic use</topic><topic>Homocysteine - blood</topic><topic>Humans</topic><topic>Hyperhomocysteinemia - prevention & control</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Renal Dialysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamadon, Mohamad Reza</creatorcontrib><creatorcontrib>Jamshidi, Lotfali</creatorcontrib><creatorcontrib>Soliemani, Alireza</creatorcontrib><creatorcontrib>Ghorbani, Raheb</creatorcontrib><creatorcontrib>Malek, Farhad</creatorcontrib><creatorcontrib>Malek, Mojtaba</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Iranian journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamadon, Mohamad Reza</au><au>Jamshidi, Lotfali</au><au>Soliemani, Alireza</au><au>Ghorbani, Raheb</au><au>Malek, Farhad</au><au>Malek, Mojtaba</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis</atitle><jtitle>Iranian journal of kidney diseases</jtitle><addtitle>Iran J Kidney Dis</addtitle><date>2011-03-01</date><risdate>2011</risdate><volume>5</volume><issue>2</issue><spage>93</spage><epage>96</epage><pages>93-96</pages><issn>1735-8582</issn><eissn>1735-8604</eissn><abstract>Hyperhomocysteinemia is common in patients with end-stage renal disease. It is one of the risk factors for cardiovascular disease. We evaluated the effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis.
Patients on maintenance hemodialysis were randomized into 4 groups to receive oral folic acid at doses of 2, 5, 10, and 15 mg/d, each for a period of 4 weeks. Serum homocysteine level was measured in all of the patients before and at the end of each week of therapy. Folic acid supplementation was discontinued during a washout period of 1 week between each of the four phases of the trial.
Thirty-one hemodialysis patients completed the four phases of treatment with each dose of folic acid (17 women and 14 men). The mean age of patients was 57.6 ± 14.6 years. Serum homocysteine level was reduced significantly compared to its basal level after treatment with folic acid at different doses (P < .001). Different doses of folic acid were not significantly different in lowering serum homocysteine levels.
Our study failed to show any difference between high-dose and low-dose folic acid therapy regarding their effect on serum homocysteine level. It seems folic acid, 2 mg/d, is an adequate dose, and there is no need to administer a higher dose of it.</abstract><cop>Iran</cop><pub>Iranian Society of Nephrology</pub><pmid>21368386</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1735-8582 |
| ispartof | Iranian journal of kidney diseases, 2011-03, Vol.5 (2), p.93-96 |
| issn | 1735-8582 1735-8604 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_855199334 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Aged, 80 and over Cross-Over Studies Female Folic Acid - administration & dosage Folic Acid - therapeutic use Homocysteine - blood Humans Hyperhomocysteinemia - prevention & control Kidney Failure, Chronic - blood Kidney Failure, Chronic - therapy Male Middle Aged Renal Dialysis |
| title | Effect of different doses of folic acid on serum homocysteine level in patients on hemodialysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T14%3A39%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20different%20doses%20of%20folic%20acid%20on%20serum%20homocysteine%20level%20in%20patients%20on%20hemodialysis&rft.jtitle=Iranian%20journal%20of%20kidney%20diseases&rft.au=Tamadon,%20Mohamad%20Reza&rft.date=2011-03-01&rft.volume=5&rft.issue=2&rft.spage=93&rft.epage=96&rft.pages=93-96&rft.issn=1735-8582&rft.eissn=1735-8604&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2324252781%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=862578650&rft_id=info:pmid/21368386&rfr_iscdi=true |